Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas (Q37288403)

19 August 2017

1 reference

title

Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas (English)

1 reference

19 August 2017

Omar Khan

1

1 reference

19 August 2017

Nicholas B La Thangue

series ordinal

2

1 reference

19 August 2017

publication date

7 October 2008

1 reference

Nature Clinical Practice Oncology

19 August 2017

published in

1 reference

19 August 2017

volume

5

1 reference

19 August 2017

issue

12

1 reference

19 August 2017

page(s)

714-726

1 reference

The cancer epigenome--components and functional correlates

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Chromatin control and cancer-drug discovery: realizing the promise

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Histone deacetylase inhibitors: gathering pace

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Histone deacetylases and cancer: causes and therapies

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Crystal structure of the nucleosome core particle at 2.8 A resolution

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Translating the Histone Code

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

An increasingly complex code

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Acetylation control of the retinoblastoma tumour-suppressor protein

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Anticancer activities of histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Histone deacetylases (HDACs): characterization of the classical HDAC family

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Histone deacetylase inhibitors: overview and perspectives

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Regulation of E2F1 activity by acetylation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Beta-catenin-histone deacetylase interactions regulate the transition of LEF1 from a transcriptional repressor to an activator

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

HDAC6-p97/VCP controlled polyubiquitin chain turnover

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

MEF2C transcription factor controls chondrocyte hypertrophy and bone development

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

The growth suppressor PML represses transcription by functionally and physically interacting with histone deacetylases

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Deacetylase inhibition promotes the generation and function of regulatory T cells.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Apoptotic and autophagic cell death induced by histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

https://api.crossref.org/works/10.1038%2FNCPONC1238

1 reference

7 January 2021

HDAC inhibitors: clinical update and mechanism-based potential.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

The diagnosis, staging, and treatment options for mycosis fungoides

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Incidence of cutaneous T cell lymphoma and other rare skin cancers in a defined population.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

WHO-EORTC classification for cutaneous lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Retroviruses and cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Mycosis fungoides and sezary syndrome: an update

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

p53 protein expression in cutaneous T-cell lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

p16(INK4a) gene alterations are frequent in lesions of mycosis fungoides

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and sezary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Microsatellite instability is associated with hypermethylation of the hMLH1 gene and reduced gene expression in mycosis fungoides

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Consequences of p16 tumor suppressor gene inactivation in mycosis fungoides and Sézary syndrome and role of the bmi-1 and ras oncogenes in disease progression.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

CDK inhibitors: positive and negative regulators of G1-phase progression

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Frequent inactivation of thep73gene by abnormal methylation or LOH in non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Aberrant promoter CpG methylation as a molecular marker for disease monitoring in natural killer cell lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Primary cutaneous lymphomas: a review with current treatment options

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Biological effects of bexarotene in cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Immunopathogenesis and therapy of cutaneous T cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in v

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Assays for pharmacodynamic analysis of histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1238

7 January 2021

Identifiers

DOI

10.1038/NCPONC1238

1 reference

release_bdemxk2qbremfc32fvhkobnc4m

19 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bdemxk2qbremfc32fvhkobnc4m

24 November 2022

mapped directly with Wikidata item

1 reference